What is Sparrow Pharmaceuticals?
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical enterprise dedicated to the development of targeted therapies for metabolic diseases. The company's core innovation centers on clofutriben, a proprietary HSD-1 inhibitor. By modulating intracellular cortisol levels, this therapeutic candidate aims to address the underlying physiological drivers of hard-to-treat type 2 diabetes and associated metabolic conditions. Through its focus on precision medicine, Sparrow Pharmaceuticals is carving out a specialized niche in the healthcare market, moving beyond traditional symptomatic treatments to address the root causes of chronic metabolic dysfunction.
How much funding has Sparrow Pharmaceuticals raised?
Sparrow Pharmaceuticals has raised a total of $206.8M across 3 funding rounds:
Series A
$50M
Stock/Share Issuance
$61.8M
Series B
$95M
Series A (2021): $50M with participation from RiverVest Venture Partners, U.S. Venture Partners, and OrbiMed
Stock/Share Issuance (2025): $61.8M, investors not publicly disclosed
Series B (2025): $95M supported by Forbion, OrbiMed, US Venture Partners, RiverVest Venture Partners, and RA Capital Management
Key Investors in Sparrow Pharmaceuticals
OrbiMed
OrbiMed is a specialized healthcare investment firm with deep expertise across biopharmaceuticals and medical devices, managing capital to support companies from early-stage ventures to established organizations.
U.S. Venture Partners
U.S. Venture Partners is a prominent Silicon Valley firm that collaborates with entrepreneurs to build transformative companies, leveraging a network of technologists and executives to support scaling and product development.
RiverVest Venture Partners
RiverVest is a venture capital firm focused on building life science companies to meet significant unmet medical needs, emphasizing a commitment to science, strategy, and innovation.
What's next for Sparrow Pharmaceuticals?
With the successful closure of this major enterprise-level funding round, Sparrow Pharmaceuticals is poised to transition into a more intensive phase of clinical development. The strategic deployment of these funds will likely prioritize the advancement of clofutriben through critical clinical trial milestones, potentially expanding the scope of its therapeutic applications. As the company scales, it will leverage the operational expertise of its investor syndicate—which includes specialists in life sciences and evidence-based healthcare investing—to navigate regulatory pathways and optimize its market entry strategy. The focus remains on validating the clinical efficacy of its lead candidate while maintaining a robust pipeline of metabolic health solutions.
See full Sparrow Pharmaceuticals company page
